**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 55-year-old woman developed reactivation of Epstein-Barr virus (EBV) secondary to haemophagocytic lymphohistiocytosis (HLH) following immunosuppressive treatment with bevacizumab, temozolomide and unspecified steroids for progressive glioblastoma \[*dosages and durations of treatments to reactions onsets not stated; not all routes stated*\].

The woman, who had been receiving bevacizumab \[Avastin\] and low-dose oral temozolomide daily as a second-line treatment for progressive glioblastoma, was hospitalised (current admission) due to worsening shortness of breath and confusion. She was found to be hypotensive, tachycardic and hypoxaemic. It was found that approximately 6 weeks prior to the current admission, she had been assessed for hypoxaemic respiratory failure. Her initial investigation for infection was negative, and she did not improve with empirical antibiotic therapy \[*specific drug not stated*\]. At that time, she was considered to have *Pneumocystis jiroveci*pneumonia (PJP) given her improvement following the initiation of unspecified steroids and cotrimoxazole \[trimethoprim with sulfamethoxazole\]. Following the initiation of cotrimoxazole, her absolute neutrophil count had decreased, and she was subsequently re-admitted with malaise, cough and was found to have a decreased absolute neutrophil count. Additionally, it was also found that she was admitted again 3 weeks prior to her current admission for an increased shortness of breath and tested positive for coronavirus. At that time, cotrimoxazole therapy was replaced by dapsone in order to continue prophylactic PJP coverage. One week prior to the current admission, it was found that her respiratory status had returned to baseline; however, her absolute lymphocyte count was low. On current admission, laboratory investigations revealed worsening pancytopenia and elevation in liver enzymes. An abdominal ultrasound and MRI demonstrated a heterogeneous liver with coarse echotexture and splenomegaly. An MRI of the brain revealed a stable appearing glioblastoma. She started receiving fluids and antibiotics \[*specific drug not stated*\]. She was found to have new warm autoantibodies and a positive direct-antiglobulin test, concerning for haemolytic anaemia. Although her total indirect and direct bilirubin were not markedly elevated, she was found to have low fibrinogen levels, elevated D-dimer and mild coagulopathy, consistent with liver injury. Viral studies showed an EBV viral load of 1 75 266 IU/mL. She had no known history of EBV infection. Given her precipitous clinical decline, liver dysfunction, pancytopenia and hypofibrinogenaemia, investigations for HLH was initiated, and she was found to have an elevated levels of ferritin, hypertriglyceridaemia and an elevated soluble IL-2 receptor, consistent with HLH. A bone marrow biopsy was not attempted given her critical condition.

The woman received methylprednisolone and immunoglobulins with little effect. She received multiple transfusions of blood, platelets and cryoprecipitate for disseminated intravascular coagulation. Rituximab was initiated, followed by daily anakinra. There was some notable response in haematologic parameters, and she required less transfusions. However, her condition continued to deteriorate. She became oliguric and an echocardiogram showed a Takotsubo-pattern cardiomyopathy. She further developed pancreatitis due to hypertriglyceridaemia. Given the extensive multiorgan failure and her family\'s wishes not to initiate dialysis or ventilator support, she passed away shortly after her care was de-escalated.
